Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Assets (2019 - 2025)

BridgeBio Pharma's Non-Current Assets history spans 7 years, with the latest figure at $138.3 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 30.39% year-over-year to $138.3 million; the TTM value through Dec 2025 reached $651.5 million, down 1.75%, while the annual FY2025 figure was $138.3 million, 30.39% down from the prior year.
  • Non-Current Assets for Q4 2025 was $138.3 million at BridgeBio Pharma, down from $158.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $220.4 million in Q3 2024 and bottomed at $65.9 million in Q1 2024.
  • The 5-year median for Non-Current Assets is $131.1 million (2021), against an average of $126.4 million.
  • The largest annual shift saw Non-Current Assets soared 296.41% in 2021 before it crashed 47.0% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $123.9 million in 2021, then plummeted by 40.14% to $74.2 million in 2022, then decreased by 7.27% to $68.8 million in 2023, then surged by 188.78% to $198.6 million in 2024, then tumbled by 30.39% to $138.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Non-Current Assets are $138.3 million (Q4 2025), $158.9 million (Q3 2025), and $167.9 million (Q2 2025).